Metropolitan Life Insurance CO Black Diamond Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$12.19 - $28.17 $73 - $169	-6 Closed	0 $0
Q1 2021 Jun 26, 2023	BUY	$22.23 - $34.75 $124,354 - $194,391	5,594 New	5,594 $136 Million
Q1 2021 May 14, 2021	SELL	$22.23 - $34.75 $124,221 - $194,183	-5,588 Reduced 99.89%	6 $136,000
Q4 2020 Jun 22, 2023	BUY	$29.47 - $35.0 $164,855 - $195,790	5,594 New	5,594 $179,000
Q3 2020 Jun 26, 2023	BUY	$26.17 - $43.07 $146,394 - $240,933	5,594 New	5,594 $169,000
Q3 2020 Mar 30, 2023	BUY	$26.17 - $43.07 $29,493 - $48,539	1,127 Added 25.23%	5,594 $169,000
Q3 2020 Nov 13, 2020	BUY	$26.17 - $43.07 $29,493 - $48,539	1,127 Added 25.23%	5,594 $169,000
Q2 2020 Jun 26, 2023	BUY	$22.3 - $44.8 $99,614 - $200,121	4,467 New	4,467 $188,000
Q1 2020 Jul 12, 2023	BUY	$18.18 - $39.48 $81,210 - $176,357	4,467 New	4,467 $111,000
Q1 2020 Mar 30, 2023	BUY	$18.18 - $39.48 $81,210 - $176,357	4,467 New	4,467 $111,000
Q1 2020 May 15, 2020	BUY	$18.18 - $39.48 $81,210 - $176,357	4,467 New	4,467 $111,000

47.6M

2.9K

69.4K

Ticker BDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,339,500
Market Cap $86.1M
Description
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.